Merck commits €1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Grant for Fertility Innovation (GFI) program by awarding grants totalling €1.5 million in 2016/17.
Sanofi Pasteur signs research agreement for Zika vaccine
- Details
- Category: Sanofi
Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the co-development of a Zika vaccine candidate.
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases.
Novo Nordisk and Aarhus University team up on world-class talents
- Details
- Category: Novo Nordisk
Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Under the new collaboration, a total of nine PhD students will be offered three-year research scholarships.
AstraZeneca enters licensing agreements with LEO Pharma in skin diseases
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic disease and Oncology. The agreements include two of AstraZeneca's potential new medicines for dermatitis and psoriasis,
Bristol-Myers Squibb and PsiOxus Therapeutics announce immuno-oncology clinical collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus' enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb's Immuno-Oncology (I-O) agent Opdivo (nivolumab) to treat a range of tumor types in late-stage cancer patients.
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
- Details
- Category: Novartis
Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.
More Pharma News ...
- New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
- Pfizer completes acquisition of Anacor
- Amgen Golden Ticket winners receive lab space and other benefits at QB3@953
- Help Pfizer change the future of healthy aging
- Merck Family Foundation established
- Roche employees raise funds for vulnerable children in over 90 communities around the world
- Sanofi announces expiration of Hart-Scott-Rodino waiting period regarding proposed acquisition of Medivation